NCT07167160

Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial

Camrelizumab Combined With Chemotherapy for Adjuvant Treatment of Cervical Cancer Patients With Pathologically Confirmed Lymph Node Positivity After Stage Surgery: A Prospective, Single-Arm, Multicenter, Phase II Clinical Trial

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 59 (estimated)
• Sponsor: Women's Hospital School Of Medicine Zhejiang University · Academic / Other
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.

Conditions

• Cervical Cancer
• Immunochemotherapy

Interventions

Type	Name	Description
DRUG	Camrelizumab combined with chemotherapy	Camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery

Timeline

• Start date: 2025-03-10
• Primary completion: 2026-12-31
• Completion: 2029-12-31
• First posted: 2025-09-11
• Last updated: 2025-12-18

Locations

1 site across 1 country: China